ECSP003322A - RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX - Google Patents

RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX

Info

Publication number
ECSP003322A
ECSP003322A ECSP003322A ECSP003322A EC SP003322 A ECSP003322 A EC SP003322A EC SP003322 A ECSP003322 A EC SP003322A EC SP003322 A ECSP003322 A EC SP003322A
Authority
EC
Ecuador
Prior art keywords
cyclodextrin
sulfobutileter
hydroxipropil
ras
rasfarnesyltransferase
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Krishnaswamy S Raghavan
Timothy M Malloy
Sailesh A Varia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP003322 priority Critical patent/ECSP003322A/en
Publication of ECSP003322A publication Critical patent/ECSP003322A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un complejo del inhibidor de la rasfarnesiltransferasa formado del inhibidor de la rasfarnesiltransferasa o una sal farmacéuticamente aceptable del mismo, de la fórmula I (gráfico), en donde n es 0 o 1, R1 se selcciona de Cl, Br, fenilo piridilo o ciano; R2 es aralquilo; R3 se selecciona de alquilo inferior, arilo o arilo sustituido o heterociclo; Z1 se selcciona de CO, SO2, CO2 o SO2NR5, R5 se selecciona de hidrógeno, alquilo inferior o alquilo sustituido; y sulfobutiléter-7-B-ciclodextrina o 2-hidroxipropil-B-ciclodextrina. El complejo tiene inesperadamente alta solubilidad acuosa del inhibidor de la rasfarnesiltransferasa son útiles como agentes anti-tumorales.A rasfarnesyltransferase inhibitor complex formed from the rasfarnesyltransferase inhibitor or a pharmaceutically acceptable salt thereof is provided, of formula I (graph), wherein n is 0 or 1, R1 is selected from Cl, Br, phenyl pyridyl or cyano; R2 is aralkyl; R3 is selected from lower alkyl, aryl, or substituted aryl or heterocycle; Z1 is selected from CO, SO2, CO2, or SO2NR5, R5 is selected from hydrogen, lower alkyl, or substituted alkyl; and sulfobutyl ether-7-B-cyclodextrin or 2-hydroxypropyl-B-cyclodextrin. The complex has unexpectedly high aqueous solubility of the rasfarnesyltransferase inhibitor being useful as anti-tumor agents.

ECSP003322 2000-01-19 2000-01-19 RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX ECSP003322A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP003322 ECSP003322A (en) 2000-01-19 2000-01-19 RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP003322 ECSP003322A (en) 2000-01-19 2000-01-19 RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX

Publications (1)

Publication Number Publication Date
ECSP003322A true ECSP003322A (en) 2000-02-24

Family

ID=42040953

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003322 ECSP003322A (en) 2000-01-19 2000-01-19 RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX

Country Status (1)

Country Link
EC (1) ECSP003322A (en)

Similar Documents

Publication Publication Date Title
LV12712A (en) Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
CO5570660A2 (en) MODIFIED C-6 INDAZOLILPIRROLOTRIAZINAS
NL300927I1 (en) tivozanib or a salt or hydrate thereof, in particular the hydrochloride monohydrate
MEP7808A (en) Process for preparing 4-trifluoromethylsulphinylpyrazole derivative
DE60028045D1 (en) NEW AMBERIC DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS
NO20044807L (en) Heratitis C virus inhibitors
CO4940458A1 (en) NOVEL INHIBITORS OF N-SUBSTITUTED UREA FOR PROTEIN TRANSFERASE FARNESILO
CO5050295A1 (en) GLUCOKINASA TRANS OLEFINAL ACTIVATORS
CO5611131A2 (en) DERIVATIVES OF 5-PHENYLTIAZOL AND ITS USE AS INHIBITORS OF PI3 CINASA
NO20062185L (en) Hepatitis C virus inhibitors
NO20013379L (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
CO5611143A2 (en) FLUOROOXINDOL PHOSPHATE PROPHARMACES
ES2188194T3 (en) 1,8-NAFTIRIDIN-4 (1H) -ONON REPLACED AS INHIBITORS OF PHOSPHODESTERASE 4.
ATE288895T1 (en) GROWTH HORMONE RELEASING OXINDOL DERIVATIVES
DK1044967T3 (en) 2-pyridinylguanidine urokinase inhibitor
CY1110284T1 (en) 2-AMINO-4-PYRIDYL-METHYL-THAIZOLINE PRODUCTS AND THEIR USE AS INDUCERS OF INDUCED SYNTHESIS
DE602006011752D1 (en) PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES SUITABLE AS ANTICOAGULATING AGENTS
ATE429429T1 (en) PHARMACEUTICAL PROCESS AND COMPOUNDS PRODUCED THEREFROM
AR063790A1 (en) DIARIL, DIPIRIDINIL AND ARILPIRIDINILDERIVADOS AND USES OF THE SAME
ES2182546T3 (en) IMIDAZO (1,2A) SUBSTITUTED AZINS AS SELECTIVE INHIBITORS OF THE COX-2.
EA200101224A1 (en) DERIVATIVES OF PURIN, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
CO5700773A2 (en) BENCIMIDAZOL DERIVATIVES
AR039122A1 (en) FTALIMIDE DERIVATIVES AS INHIBITORS OF MONOAMINO OXIDASA B
CO5251424A1 (en) USEFUL OXAZINQUINOLONES IN THE TREATMENT OF VIRAL INFECTIONS
ECSP003322A (en) RAS- FARNESIL TRANSFERASE AND SULFOBUTILETER -7-ß- CYCLODEXTRIN OR 2- HYDROXIPROPIL - ß - CYCLODEXTRIN AND METHOD INHIBITOR COMPLEX